• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >Necitumumab in the treatment of advanced non-small cell lung cancer: translation from preclinical to clinical development.
【24h】

Necitumumab in the treatment of advanced non-small cell lung cancer: translation from preclinical to clinical development.

机译：Necitumumab在治疗晚期非小细胞肺癌中的作用：从临床前到临床的发展。

获取原文
获取原文并翻译 | 示例
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

INTRODUCTION: Treatment outcomes in unselected patients with advanced NSCLC remain disappointing with platinum-based chemotherapy. The addition of monoclonal antibodies targeting EGFR to standard first-line therapy is a validated strategy and has been associated with statistically significant survival advantage in advanced NSCLC. Necitumunab is a fully human IgG1 monoclonal antibody targeting EGFR, having the potential benefit of lower hypersensitivity reaction risk as compared with cetuximab and also equivalent antibody-dependent cell-mediated cytotoxicity. AREAS COVERED: This paper reviews literature on preclinical and early clinical development of necitumumab that is available in PubMed and published abstracts from conferences, as well as ongoing trials as specified by clinicaltrials.gov. Recently, the Phase III clinical trial evaluating the addition of necitumumab to pemetrexed and cisplatin in non-squamous NSCLC was prematurely closed due to concerns about the increased risk of thromboembolic events in the experimental arm. Accrual in the Phase III trial of necitumumab in combination with gemcitabine and cisplatin in squamous NSCLC is ongoing. EXPERT OPINION: Results of the ongoing large randomized trials will be instrumental in determining the drug's clinical significance and, with the analysis of potential molecular predictive factors, are expected to bring valuable additions to future therapeutic strategies in NSCLC.
机译：简介：未经选择的晚期非小细胞肺癌患者的治疗结局仍然令人失望，铂类化疗。将靶向EGFR的单克隆抗体添加到标准一线治疗中是一种经过验证的策略，并且与晚期NSCLC中具有统计学意义的生存优势相关。 Necitumunab是靶向EGFR的完全人IgG1单克隆抗体，与西妥昔单抗相比具有降低超敏反应风险的潜在好处，并且具有等效的抗体依赖性细胞介导的细胞毒性。覆盖的领域：本文回顾了尼西单抗的临床前和早期临床开发文献，这些文献可在PubMed中获得，并从会议上发表摘要，以及Clinicaltrials.gov指定的正在进行的试验。最近，由于担心实验组中血栓栓塞事件的风险增加，因此评估了在非鳞状非小细胞肺癌中在培美曲塞和顺铂中添加尼西单抗的III期临床试验已提前结束。 necitumumab联合吉西他滨和顺铂在鳞状NSCLC的III期试验中的研究正在进行中。专家意见：正在进行的大型随机试验的结果将有助于确定该药物的临床意义，并通过分析潜在的分子预测因素，有望为NSCLC的未来治疗策略带来有价值的补充。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号